10-Q quarterly report · filed Oct 28, 2026

ClearPoint Neuro, Inc. (CLPT) Q3 2026 10-Q Quarterly Report

Short answer

ClearPoint Neuro, Inc. (CLPT) filed its Q3 2026 10-Q quarterly report on Oct 28, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $12M (up 36.3% year over year) with net income of −$7M.

Q3 2026 key financials · XBRL

Revenue
$12M
+36.3% YoY · +11.0% QoQ
Net income
−$7M
−26.6% YoY · +34.2% QoQ
Operating margin
-52.4%
Gross margin
58.5%
EPS (diluted)
−$0.24
−14.3% YoY · +36.8% QoQ

Source: XBRL data from the ClearPoint Neuro, Inc. (CLPT) Q3 2026 10-Q on SEC EDGAR. USD.

ClearPoint Neuro, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $12.1M, up 36% YoY from $8.9M
  • Gross margin 58% vs 63% YoY, with gross profit $7.1M vs $5.6M
  • Best segment: neurosurgery navigation and therapy revenue $5.4M, up 59% YoY
  • Worst segment: biologics disposable products $1.2M, down 8% YoY
  • Cash $46.2M; nine-month operating cash use $20.1M, ATM proceeds $22.0M supporting liquidity for at least twelve months

Risk Factors

  • New risk: CAL preclinical CRO facility investment, triggered by ongoing build-out and operations
  • Operational risk: construction, permitting, equipment, or vendor delays could restrict CAL capacity and service offerings
  • Regulatory risk: failure to achieve or maintain GLP compliance could prevent GLP study performance
  • Market risk: insufficient customer demand or delayed statements of work could leave CAL underutilized
  • Financial risk: CAL lease expires approximately eleven years after final premises delivery, with fixed rent and annual increases

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other ClearPoint Neuro, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.